Notcovich S, deNicolo G, Williamson N B, Grinberg A, Lopez-Villalobos N, Petrovski K R
a Institute of Veterinary, Animal and Biomedical Sciences , Massey University , Palmerston North 4442 , New Zealand.
b Current address: AgResearch, Private Bag 4749, Christchurch 8140, New Zealand.
N Z Vet J. 2016 Jul;64(4):218-23. doi: 10.1080/00480169.2016.1157049. Epub 2016 Mar 9.
To compare the ability of four strains of Streptococcus uberis at two doses to induce clinical mastitis in lactating dairy cows after intramammary inoculation in order to evaluate their usefulness for future experimental infection models.
Four field strains of S. uberis (26LB, S418, and S523 and SR115) were obtained from cows with clinical mastitis in the Wairarapa and Waikato regions of New Zealand. Twenty-four crossbred lactating cows, with no history of mastitis and absence of major pathogens following culture of milk samples, were randomly allocated to four groups (one per strain) of six cows. Each cow was infused (Day 0) in one quarter with approximately 10(4) cfu and in the contralateral quarter with approximately 10(6) cfu of the same strain. The other two quarters remained unchallenged. All four quarters were then inspected for signs of clinical mastitis, by palpation and observation of the foremilk, twice daily from Days 0-9, and composite milk samples were collected from Days 0-8 for analysis of somatic cell counts (SCC). Quarters were treated with penicillin when clinical mastitis was observed. Duplicate milk samples were collected and cultured on presentation of each clinical case and on Day 4 from challenged quarters with no clinical signs.
Clinical mastitis was diagnosed in 26/48 (54%) challenged quarters. Challenge with strain S418 resulted in more cases of mastitis (12/12 quarters) than strains SR115 (7/12), 26LB (6/12) or S523 (1/12), and the mean interval from challenge to first diagnosis of mastitis was shorter for S418 than the other strains (p<0.001). The proportion of quarters from which S. uberis could be isolated after challenge was less for strain 26LB (1/6) than SR115 (6/7) (p<0.05), and SCC following challenge was lower for strain S523 than the other strains (p<0.05).
There were significant differences between the strains in the proportion of quarters developing clinical mastitis, the interval to mastitis onset, SCC following challenge and the proportion of clinical cases from which S. uberis could be isolated. These results illustrate the difference in the ability of S. uberis strains to cause mastitis and the severity of the infections caused.
Experimental challenge models can be used to compare infectivity and pathogenicity of different strains of mastitis-causing bacteria, the efficacy of pharmaceutical products and host-responses in a cost-effective manner.
比较四株乳房链球菌在两种剂量下经乳房内接种后诱导泌乳奶牛临床型乳房炎的能力,以评估它们在未来实验感染模型中的实用性。
从新西兰怀拉拉帕和怀卡托地区患有临床型乳房炎的奶牛中获取四株乳房链球菌野外菌株(26LB、S418、S523和SR115)。24头无乳房炎病史且乳汁样本培养后无主要病原体的杂交泌乳奶牛被随机分为四组(每组一株菌株),每组6头。每头奶牛在第0天,一个乳区注入约10⁴ cfu同一菌株,对侧乳区注入约10⁶ cfu同一菌株。另外两个乳区不进行接种。然后从第0天至第9天每天两次通过触诊和观察初乳检查所有四个乳区是否有临床型乳房炎迹象,并在第0天至第8天采集混合乳汁样本分析体细胞计数(SCC)。观察到临床型乳房炎时,乳区用青霉素治疗。每个临床病例出现时以及第4天从无临床症状的接种乳区采集两份乳汁样本进行培养。
48个接种乳区中有26个(54%)被诊断为临床型乳房炎。用S418菌株接种导致的乳房炎病例(12/12个乳区)比SR115菌株(7/12)、26LB菌株(6/12)或S523菌株(1/12)更多,且S418菌株从接种到首次诊断乳房炎的平均间隔时间比其他菌株短(p<0.001)。接种后能分离出乳房链球菌的乳区比例,26LB菌株(1/6)低于SR115菌株(6/7)(p<0.05),接种后SCC,S523菌株低于其他菌株(p<0.05)。
各菌株在发生临床型乳房炎的乳区比例、乳房炎发病间隔时间、接种后的SCC以及能分离出乳房链球菌的临床病例比例方面存在显著差异。这些结果说明了乳房链球菌菌株引起乳房炎的能力以及所导致感染严重程度的差异。
实验性接种模型可用于以经济有效的方式比较不同引起乳房炎细菌菌株的传染性和致病性、药物产品的疗效以及宿主反应。